EARNINGS PRESENTATION Q4 2025 February 26, 2026 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may ...

Forward-looking statements Integra LifeSciences J.P. Morgan Healthcare Conference January 2026 Slide 2 A global medtech leader dedicated to restoring lives Demonstrated leadership in $9B global market Extensive portfolio of best-in-class products Executing strategic transformation Strengthening operational foundation Enabling growth and innovation 19% LTM adjusted EBTIDA margin 62.8% LTM adjusted gross margin $1.6B LTM reported revenue $89M LTM operating cash flow Slide 3 Financial metrics shown for the tra ...

Financial Performance - Q3 2025 revenue grew organically by 5% compared to Q3 2024[8, 9] - Adjusted EPS for Q3 2025 was $054, a 317% increase compared to $041 in Q3 2024[7, 10] - Adjusted EBITDA margin for Q3 2025 was 195%, a 330 bps increase compared to 162% in Q3 2024[10] - Q3 2025 operating cash flow was $409 million with a free cash flow conversion of 619%[11] Segment Performance - Codman Specialty Surgical (CSS) Q3 2025 revenue was $2926 million, with organic growth of 71% compared to Q3 2024[13] - Tissue Technologies Q3 2025 revenue was $1095 million, a 03% organic decrease compared to Q3 2024[17] Guidance and Outlook - Q4 2025 reported revenue is projected to be between $420 million and $440 million, with organic growth ranging from -59% to -14%[26] - Full year 2025 reported revenue is projected to be between $162 billion and $164 billion, with organic growth ranging from -16% to -04%[27, 28] - Full year 2025 adjusted EPS is projected to be between $219 and $224[28]